Interim analysis of metabolic modulators shows efficacy in NAFLD

Axcella released an update from the ongoing clinical study of two potential therapies for nonalcoholic fatty liver disease that showed the compounds were safe, well-tolerated, and demonstrated relevant clinical response, according to a press release.“These interim noninvasive data indicate that AXA1125 and AXA1957 are having a positive impact on multiple dysregulated biological pathways related to health and disease that are common in NAFLD [and nonalcoholic steatohepatitis] patients,” Stephen A. Harrison, MD, from Pinnacle Clinical Research in San Antonio, Texas, and principalRead More